Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) to Post -$1.63 EPS

Analysts predict that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will report ($1.63) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.73) to ($1.55). Agios Pharmaceuticals posted earnings of ($1.59) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 2.5%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.01) per share for the current year, with EPS estimates ranging from ($6.22) to ($5.90). For the next financial year, analysts expect that the firm will post earnings of ($5.97) per share, with EPS estimates ranging from ($6.10) to ($5.68). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The firm had revenue of $40.40 million during the quarter, compared to analysts’ expectations of $12.47 million. During the same quarter in the previous year, the company posted ($1.78) EPS. Agios Pharmaceuticals’s revenue was up 257.5% on a year-over-year basis.

Several research analysts recently weighed in on the stock. BidaskClub cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Piper Jaffray Companies restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 4th. Cann restated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. SunTrust Banks restated a “buy” rating and issued a $123.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, July 23rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, August 2nd. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $97.90.

AGIO stock traded down $0.41 during trading on Friday, hitting $73.56. The company had a trading volume of 503,600 shares, compared to its average volume of 446,340. Agios Pharmaceuticals has a 12 month low of $51.62 and a 12 month high of $99.82. The stock has a market capitalization of $4.20 billion, a PE ratio of -10.88 and a beta of 1.77.

In other Agios Pharmaceuticals news, insider Steven L. Hoerter sold 2,050 shares of the company’s stock in a transaction on Wednesday, July 25th. The shares were sold at an average price of $84.58, for a total transaction of $173,389.00. Following the completion of the sale, the insider now owns 2,050 shares in the company, valued at approximately $173,389. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $83.50, for a total transaction of $250,500.00. Following the sale, the insider now owns 60,196 shares of the company’s stock, valued at approximately $5,026,366. The disclosure for this sale can be found here. Insiders have sold a total of 28,627 shares of company stock valued at $2,212,296 in the last quarter. Corporate insiders own 3.02% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Tiverton Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $142,000. Strs Ohio bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $179,000. NewSquare Capital LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $182,000. Barrett Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $253,000. Finally, M&T Bank Corp bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at $293,000. Institutional investors own 93.64% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Featured Article: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply